Teva Elotinib Tablet 150 mg (Elotinib Hydrochloride)

Adult dose

Non-small cell lung cancer: Take 150mg of this medicine once daily at least 1 hour before or at least 2 hours after a meal. Treatment may be continued until disease progression or unacceptable toxicity occurs. Pancreatic cancer: In combination with gemcitabine, take 100mg of this medicine once daily at least 1 hour before or at least 2 hours after a meal. Treatment may be continued until disease progression or unacceptable toxicity occurs. Reduce the dose or temporarily interrupt treatment in patients with severe diarrhea that does not respond to loperamide or is accompanied by dehydration. Reduce the dose or temporarily interrupt treatment in patients with severe skin reactions as well. If dose reduction is necessary, reduce the dose in 50mg increments. Consider dose reduction if severe adverse reactions occur in patients receiving concomitant strong CYP3A4 inhibitors such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole, or grapefruit juice. If no alternative medicine is available, consider administering more than 150mg for non-small cell lung cancer or more than 100mg for pancreatic cancer, and monitor the patient's safety to confirm tolerability. If the dose of this medicine has been increased, reduce its dose when rifampicin or another inducer is discontinued. If severe adverse reactions occur, consider reducing the dose of or discontinuing this medicine. The maximum tolerated dose of this medicine in current smokers with non-small cell lung cancer is 300mg. In patients who continue to smoke, administration of a 300mg dose as second-line therapy after chemotherapy did not improve efficacy compared with the recommended dose of 150mg.

This medication may cause serious lung issues; therefore, if symptoms such as shortness of breath, cough, or fever develop or worsen, it should be discontinued immediately and a physician consulted. Caution is required as heart problems may arise, especially in patients with a history of myocardial infarction or circulatory issues. Serious brain conditions, such as cerebrovascular accidents, may occur, necessitating immediate notification to medical staff of related symptoms. There is a risk of hemolytic anemia due to decreased platelet count, so caution is advised if abnormal symptoms appear. Symptoms such as diarrhea, dehydration, electrolyte imbalance, and renal failure can occur; appropriate treatment and hydration are necessary if diarrhea is severe or lasts long. Since liver function may be affected, patients with liver disease or those taking hepatotoxic drugs should have regular liver function tests, and treatment may be discontinued if liver function abnormalities are detected. Gastrointestinal perforation may rarely occur, with increased risks in patients with digestive disorders or those taking certain medications. Severe blistering skin diseases may manifest, necessitating immediate consultation with a doctor if any skin abnormalities develop, and discontinuation if symptoms are severe. Inflammation of the eyes or corneal ulcers may rarely occur; immediate consultation with an ophthalmologist is required if there are symptoms such as eye pain or blurred vision. This medication should not be administered to patients with specific genetic diseases or allergies to its components. Patients with impaired liver or kidney function should always consult with a physician before taking this medication, and those with liver impairment require more caution. Common side effects include rash, diarrhea, loss of appetite, fatigue, shortness of breath, so if any abnormal symptoms arise, consult a physician. This medication may interact with other drugs, especially those affecting liver metabolism or acid-reducing medications, requiring caution when administered together. Women who are pregnant or may become pregnant should avoid conception while taking this drug, and it is advisable to avoid it during breastfeeding. Safety in pediatric patients has not been established; caution is required for use in children. Elderly patients can use this drug without special dosage adjustments, but caution is necessary if side effects occur. Overdose can result in serious side effects such as diarrhea, rash, liver dysfunction; strict adherence to the prescribed dosage is essential. Keep this medication out of reach of children and avoid transferring it to other containers. If any abnormal symptoms arise during treatment, consult a physician immediately and have regular liver function and blood tests.

Interstitial lung disease-like symptoms, pneumonia, radiation pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obstructive bronchiolitis, pulmonary fibrosis, acute respiratory distress syndrome, pulmonary infiltrates, dyspnea, cough, fever, myocardial infarction, ischemia, cerebrovascular accident, microangiopathic hemolytic anemia associated with thrombocytopenia, diarrhea, dehydration, electrolyte imbalance, renal failure, hepatitis, acute hepatitis, hepatic failure, gastrointestinal perforation, vesicular and exfoliative skin disorders, Stevens-Johnson syndrome, toxic epidermal necrolysis, corneal perforation, corneal ulcer, abnormal eyelash growth, dry conjunctivitis, keratitis, rash, appetite loss, fatigue, nausea, infection, vomiting, stomatitis, itching, skin dryness, conjunctivitis, dry conjunctivitis, abdominal pain, vaccine side effects, weight loss, edema, fever, constipation, bone pain, myalgia, depression, dyspepsia, dizziness, headache, insomnia, alopecia, anxiety, neuropathy, distension, rigidity, deep vein thrombosis, thrombotic adverse reaction, syncope, arrhythmia, intestinal lung disease, pancreatitis, thrombocytopenia, cerebral hemorrhage, abnormal liver function, gastrointestinal bleeding, hematemesis, bloody stool, melena, eyelash entrapment, excessive eyelash growth, hypertrophy, hepatitis, acute hepatitis, hypokalemia, acute renal failure, epistaxis, acne, folliculitis, skin fissures, hyperpigmentation, paronychia, hirsutism, nail fragility, nail shaking, pneumonia, disease exacerbation, respiratory function failure, systemic weakness, hemoptysis, sepsis, pulmonary embolism, mucositis, sputum, uveitis, intestinal emphysema, hepatorenal syndrome, bleeding, rhabdomyolysis, myopathy

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain the storage temperature between 15 to 30 degrees Celsius.

Appearance

White or nearly white round film-coated tablet

Package unit

30 tablets (10 tablets/PTPX3)